Caribou Biosciences

CRBUNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$163.648 M

$1.65 +0.61%

Close of 7 Aug 2026

Revenue

$11.2M

#3147 by revenue

Earnings

-$148.1M

Loss-making

Shares outstanding

99,180,575

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#103LENZ TherapeuticsLENZ$168.1M
#104Cardiol TherapeuticsCRDL$163.7M
#105Caribou BiosciencesCRBU$163.6M
#106Molecular PartnersMOLN$163.5M
#107Tenaya TherapeuticsTNYA$163.0M

Where these numbers come from

Share counts and financials for Caribou Biosciences are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.